Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD). Mov Disord 2013;28:1823-31.

Group, Parkinson Study. 2013. “Phase II Safety, Tolerability, and Dose Selection Study of Isradipine As a Potential Disease-Modifying Intervention in Early Parkinson’s Disease (STEADY-PD). Mov Disord 2013;28:1823-31.”. Mov Disord.